You are currently viewing NewStem’s diagnostic kit can predict resistance to chemotherapy

The breakthrough diagnostic kit under development by NewStem can predict if a tumor will develop resistance to drugs, making therapy ineffective. The technology is based on research of Prof. Nissim Benvenisty at the Hebrew University of Jerusalem and was acquired under an exclusive license from Yissum Research Development Company, university’s the technology-transfer company. NewStem’s CEO is Ayelet Dilion-Mashiah.

For more information, see: